Abstract submissions are open for the R for Health Technology Assessment (HTA) workshop hosted by St. Anne’s College, University of Oxford, on May 19th-20th and the 23rd, 2022. The workshop is a daylong in-person hybrid event showcasing presentations on using R for HTA-related purposes. Participants […]
Are Virtual Advisory Boards Here to Stay?
The COVID-19 pandemic hastened the transition from in-person advisory board meetings to a virtual format. However, this was not a smooth change, and challenges for successful and engaging adoption of entirely-online advisory meetings still remain. In a recent MAP Newsletter, authors break down these […]
AJMC Study: Projected US Savings from Biosimilars, 2021-2025
In a recent study published in the American Journal of Managed Care, researchers Andrew Mulcahy, PhD, and colleagues project US spending on biosimilars and estimate the total savings provided by them from 2021-2025. Mulcahy et al. estimate that biosimilars would save $38.4 billion in this time frame […]
New Independent Directors Appointed by Syneos
Syneos Health has announced that it has appointed Barbara W. Bodem and Alfonso G. Zulueta to its Board of Directors. The two new independent directors bring their insights to help the company’s customers get their therapeutics to patients. Bodem was the Senior Vice President and Chief Financial […]
Rare Disease Clinical Outcome Assessment Consortium Announced by C-Path
The Critical Path Institute (C-Path) has launched its Rare Disease Clinical Outcome Assessment Consortium. The Consortium is a public-private collaborative effort to help select clinical outcome assessment parameters for therapeutics and products targeting rare diseases. Partners in this effort […]
Clarivate Releases 2022 Drugs to Watch List
Clarivate has released their 2022 Drugs to Watch list. The list includes seven experimental therapeutics in the pipeline that have the potential to advance public health and become heavy hitters for pharma. These drugs include lecanemab, an Alzheimer’s drug, adagrasib, a cancer drug, and the type 2 […]
US faces ‘critical moment’ in pricing reform that ‘won’t come again,’ nonprofit founder says after tallying 554 new hikes
With 2021 over, the pharmaceutical industry kicked off the New Year with one of its favorite pastimes: raising the prices on hundreds of branded meds. Public and political scrutiny didn’t stop many of the world's top drugmakers from partaking in the customary practice. Still, a shot at […]
A holistic approach to market access in emerging markets
Although his focus is usually on the APAC region, Jeff’s observations can be applied to emerging markets in other parts of the world, including Africa and Latin America. Though each market has its own unique features, grouping markets into archetypes can be a useful approach in developing access […]
Why Are Physicians Silent About Outrageous Drug Prices?
One of the bizarre aspects of drug pricing in the U.S. is that the government is not permitted by law to negotiate the prices of drugs with pharmaceutical manufacturers. In most of the world markets, the national health authority in each country engages in long (and often difficult) discussions with […]
Supply chain middlemen ‘pocket half of US branded medicine spending’
In 2020, over half of total spending on brand medicines went to the supply chain, middlemen and other stakeholders, overtaking the amount going to drug manufacturers for the first time, according to a new study. The report from Berkeley Research Group (BRG) – which was funded by the pharma […]
Innovation and access: Improving Europe’s pharmaceutical regulatory framework
EMA “lags behind” other international regulators when it comes to approval timelines, finds EFPIA analysis. Only a regulatory framework that “embraces a culture of excellence and innovation” will make Europe a world leader in life sciences and ensure people can reap the benefits of life-changing […]
NORD’s Rare Cancer Coalition 2021 Year In Review
Jan. 12, 2022 TOPIC: Patients & Members [NORD’s Rare Cancer Coalition 2021 Year In Review] Posted by Maia Craig NORD’s Rare Cancer Coalition (RCC) worked hard in 2021 to raise awareness for rare cancers and tackle issues that patients and caregivers face, such as access to care, treatments, and […]
C-Path Launches Rare Disease Clinical Outcome Assessment Consortium
The Rare Disease COA Consortium aims to advance patient-focused assessment of clinical benefit in treatment trials for rare diseases TUCSON, the launch of the a public-private partnership focused on optimizing COA selection during medical product development for rare diseases. The Rare Disease COA […]
UNC researchers awarded $4.3M from PCORI to study strategies to improve health outcomes for youth with intellectual and developmental disabilities and their parents
Kathleen C Thomas, PhD, MPH of the UNC Eshelman School of Pharmacy will lead a comparative effectiveness research study to improve health outcomes for youth with intellectual and developmental disability (IDD) and their parents through two parent peer group interventions, one parent-directed and one […]
Turning the deluge of health data into actionable health analytics
At the time, the HITECH Law 2009 and the introduction of the meaningful use program represented a momentous step in the digital transformation of healthcare. With billions of dollars in investment and government incentives in almost two years, more than 77% of hospitals had reached stage 3 of the […]
J&J’s investment arm joins $150M investment in digital health firm Verana
Medical full body screening software on tablet and healthcare devices Verana Health, a company that analyzes real-world patient data to provide insights about drugs, has raised $150 million to fuel an expansion of its technology. Data from more than 20,000 healthcare providers and 70 electronic […]
DNA Explainer: Why Govt plans to study drug pricing policies of other countries
Centre is planning to start a study on drug pricing policies of at least 10 countries, including China, Sri Lanka, Bangladesh and the United States. This comes at a time when prices of medicines are going up and the ongoing Covid-19 pandemic has added to the woes. The affordability of medicines is a […]
Klobuchar optimistic Medicare will be given some power to negotiate drug prices
Klobuchar optimistic Medicare will be given some power to negotiate drug prices U.S. Sen. Amy Klobuchar says there’s no good reason why Medicare is barred by law from being able to use its clout to negotiate lower prescription drug prices. The Minnesota Democrat has been calling for a law change […]
The Drug Industry Might Have Dodged A Build Back Better Bullet But Remains In Congressional Crosshairs
The Biden administration’s campaign to rehabilitate the drug price negotiation legislation contained in the stalled Build Back Better bill (BBB), appears to have been sidelined for now. Reluctant senators and Covid-19 have all but eliminated any new year’s momentum to pass it. With time running out, […]
Healthcare Electronic Data Interchange Market Analysis By Size, Share, Opportunities, Growth, Emerging Technologies, And Regional Forecast To 2027
Healthcare Electronic Data Interchange Market Scope Market Research Future (MRFR) expects the healthcare electronic data interchange (EDI) market to thrive at a rate of 8.8% over the review period, which is between 2020 and 2027. Major Growth Boosters and Challenges Electronic data interchange […]
Drug Discovery Informatics Market size worth $ 6.25 Billion, Globally, by 2028 at 11.3% CAGR: Verified Market Research®
Owing to the growing demand for the new medication moieties, rising implementation of in-silico form tools, the increasing amount of drug discovery statistics, will boost the market in the near future. JERSEY CITY, N.J. , Jan. 12, 2022 /PRNewswire/ -- Verified Market Research recently published a […]
Sanders Statement on Medicare Limiting Coverage for Alzheimer’s Drug
Sanders Statement on Medicare Limiting Coverage for Alzheimer’s Drug WASHINGTON - Sen. Bernie Sanders (I-Vt.) Tuesday issued the following statement after the Centers for Medicare and Medicaid Services (CMS) proposed a rule that would cover Aduhelm, the outrageously expensive Alzheimer’s treatment, […]
Martin Shkreli Barred From Drug Industry and Must Repay $64.6 Million
Martin Shkreli, the former pharmaceutical executive best known for unapologetically raising the price of an old drug, must pay $64.6 million and will be barred for life from the drug industry for violating antitrust law in connection with that medicine, a federal court ordered on Friday . Mr. […]
ICER Releases Evidence Report for Type 2 Diabetes Drug Tirzepatide
The Institute for Clinical and Economic Review (ICER) has released their revised evidence report for Eli Lilly’s new type 2 diabetes drug tirzepatide. The drug is intended as an adjunct therapy for metformin and is more effective than injectable semaglutide, another adjunct therapy. A virtual public […]
The Minister of Health announces that the self-diagnostic antigen tests will have a maximum price of 2.94 euro
The Minister of Health, Carolina Darias, has reported the agreement reached to limit the maximum price of the COVID-19 self-diagnostic antigen tests to 2.94 euro after the completion of the meeting of the Interministerial Commission on Drug Prices . The Interministerial Drug Price Commission is the […]
medical leverage, a communications company positions itself for 2022 growth
CARY, N.C. medical leverage, a communications company (ml) is pleased to announce the promotion of Justin Reed to VP of Finance, Alexandra Rivers to HR and Training Manager, and Janeanne Josephson to Associate Marketing Manager. These changes drive the company's mission to meet the challenges of […]
AscellaHealth Expands Pharmaceutical Services for Life Sciences: Pre-Commercialization and Outsourced Market Access Solutions and Patient Support & Hub Services Ensure Optimal Access and Clinical Outcomes | Business Wire
BERWYN, Pa.--( BUSINESS WIRE )-- AscellaHealth , a global specialty pharmacy and healthcare solutions company, announces a comprehensive suite of Specialty Pharmacy (SP) services, including pre-commercialization, outsourced market access, wholesale, 3PL, limited distribution drug (LDD) fulfillment, […]
GigXR Partners With Leading Medical Education Programs to Develop Healthcare Simulation Metaverse
GigXR Partners With Leading Medical Education Programs to Develop Metaverse Healthcare simulation in 2022 has an opportunity to address key challenges facing the industry. Safe-to-fail training provides an ideal environment for learners to practice vital skills ranging from common procedures to […]
Chinese diabetics to enjoy favorable drug prices from May – People’s Daily Online
BEIJING, Jan. 12 (Xinhua) -- Starting from May, diabetes patients in China will enjoy an average 48 percent drop in their medicine costs. The price cut will be effective on about 40 commonly used insulin products selected by the country's centralized drug procurement program in November. The […]
Forbes: 2022 Economy, Politics, and Drug Pricing Legislation Predictions
In a Forbes piece published early this month, Joshua Cohen makes predictions about the economy, politics, and drug pricing reform in 2022. Cohen foresees a slow but steady economic recovery and a slight easing of inflation. He also predicts that the Democrats will cling to their House majority and […]
